| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G |
| 12 Nov 2026 | 10-Q |
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
Listed on the Nasdaq Global Market under the ticker symbol “SCTX,” and raised capital to fund the initial clinical development of STX-1150, STX-1200, and STX-1400 |
| 02 Sep 2026 | 10-Q |
| 02 Sep 2026 |
8-K: Results of Operations and Financial Condition
Initiated the first-in-human Phase 1 trial of STX-1150, a novel LDL-C lowering therapy powered by ELXR, a highly engineered epigenetic silencing technology designed to deliver ultra-long-acting cholesterol lowering without permanent gene... |
| 03 Aug 2026 | SCHEDULE 13G |
| 30 Jul 2026 | SCHEDULE 13D |
| 30 Jul 2026 | SCHEDULE 13D |
| 29 Jul 2026 |
Form 4: Orbimed Advisors Llc, Director and 1 other
Received 348,825 shares by conversion · Bought 1,000,000 shares ($15M) |
| 29 Jul 2026 | SCHEDULE 13D |
| 29 Jul 2026 |
Form 4: Gordon Carl L, Director
Received 348,825 shares by conversion · Bought 1,000,000 shares ($15M) |
| 29 Jul 2026 |
Form 4: Ah Bio Fund II, L.p., 10% owner and 5 others
Received 2,749,392 shares by conversion · Bought 333,333 shares ($5M) |
| 29 Jul 2026 |
Form 4: Doudna Jennifer A, 10% owner
Received 12,511 shares by conversion |
| 28 Jul 2026 |
Form 4: Aghazadeh Behzad, Director and 2 others
Bought 2,383,333 shares ($36.1M) · Bought 7,905 shares ($144K) |
| 28 Jul 2026 |
Form 4: Staahl Brett, 10% owner
Granted 4,755 Stock Option (Right to Buy) · Granted 19,385 Stock Option (Right to Buy) · Granted 19,385 Performance-based Stock Option (Right to Buy) |
| 27 Jul 2026 |
Form 4: Lucas Svetlana, Chief Business Officer
Granted 9,547 Stock Option (Right to Buy) · Bought 3,000 shares ($45K) · Granted 109,426 Stock Option (Right to Buy) · 1 more |
| 27 Jul 2026 |
Form 4: Oakes Benjamin L., Director
Granted 12,969 Stock Option (Right to Buy) · Granted 264,784 Stock Option (Right to Buy) · Granted 429,599 Performance-based Stock Option (Right to Buy) |
| 27 Jul 2026 |
Form 4: Gordon Carl L, Director
Granted 14,725 Stock Option (Right to Buy) |
| 27 Jul 2026 |
Form 4: Watson James Dean, Director
Granted 14,725 Stock Option (Right to Buy) |
| 27 Jul 2026 |
Form 4: Bleharski Joshua, Director
Granted 14,725 Stock Option (Right to Buy) |
Loading...